Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | TYMP | P19971 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6046977 | 0.88 | POLB (0.50) | POLBLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL6890940 | 0.88 | TYMP (0.41) | TYMPNPC1RAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL7047161 | 0.87 | POLB (0.39) | POLBTYMPNPC1RAB9ALMNA | |
| SCHEMBL8712130 | 0.87 | POLB (0.42) | POLBTYMPNPC1RAB9ALMNA | |
| SCHEMBL6046979 | 0.84 | TYMP (0.45) | POLBTYMPNPC1RAB9ALMNA | |
| SCHEMBL6046965 | 0.81 | NT5E (0.40) | POLBLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL6046960 | 0.80 | POLB (0.35) | POLBALDH1A1MAPT | |
| SCHEMBL6047022 | 0.78 | POLB (0.34) | POLB | |
| SCHEMBL6046985 | 0.77 | RNASE1 (0.49) | — | |
| SCHEMBL6046988 | 0.77 | RNASE1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154256-A1 | Method for covalently attaching nucleosides and/or nucleotides on surfaces and method for determining coupling yields in the synthesis of nucleotides | CHEMOGENIX GMBH (DE) | 2006-07-13 | — | — | US | disclosed |
| EP-1438322-A2 | METHOD FOR COVALENTLY ATTACHING NUCLEOSIDES AND/OR NUCLEOTIDES ON SURFACES AND METHOD FOR DETERMINING COUPLING YIELDS IN THE SYNTHESIS OF NUCLEOTIDES | Chemogenix GmbH (DE) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003035664-A2 | METHOD FOR COVALENTLY ATTACHING NUCLEOSIDES AND/OR NUCLEOTIDES ON SURFACES AND METHOD FOR DETERMINING COUPLING YIELDS IN THE SYNTHESIS OF NUCLEOTIDES | CHEMOGENIX GMBH (DE) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154256-A1 | Method for covalently attaching nucleosides and/or nucleotides on surfaces and method for determining coupling yields in the synthesis of nucleotides | NUDT1, PNP, NME2 | POLB 220/4885TYMP 13/4885NPC1 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.